Sana Biotechnology develops engineered cell therapies using ex vivo and in vivo platforms. Its lead programs include SC451, a HIP-modified stem cell-derived pancreatic islet cell therapy for type 1 diabetes, and SG293, an in vivo CD8-targeted fusosome CAR T product for B cell malignancies and autoimmune diseases. The company previously pursued allogeneic CAR T programs (SC291, SC262) but suspended those in November 2025 to focus on its two lead candidates.
expected 2027-02-04
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-03 | 2025-12-31 | 0001193125-26-088215 | EDGAR | 143K words |
| 2025-03-17 | 2024-12-31 | 0000950170-25-040254 | EDGAR | 141K words |
| 2024-02-29 | 2023-12-31 | 0000950170-24-023119 | EDGAR | 139K words |
| 2023-03-16 | 2022-12-31 | 0001564590-23-003798 | EDGAR | 137K words |
| 2022-03-16 | 2021-12-31 | 0001564590-22-010539 | EDGAR | 136K words |
| 2021-03-24 | 2020-12-31 | 0001193125-21-092650 | EDGAR | 150K words |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-11-05 | 2026-09-30 | 0001193125-26-449836 | EDGAR | 94K words |
| 2026-08-10 | 2026-06-30 | 0001193125-26-342395 | EDGAR | 92K words |
| 2025-11-06 | 2025-09-30 | 0001193125-25-269569 | EDGAR | 91K words |
| 2025-08-11 | 2025-06-30 | 0001770121-25-000010 | EDGAR | 90K words |
| 2025-05-08 | 2025-03-31 | 0000950170-25-066943 | EDGAR | 86K words |
| 2024-11-08 | 2024-09-30 | 0000950170-24-123730 | EDGAR | 87K words |
| 2024-08-08 | 2024-06-30 | 0000950170-24-094052 | EDGAR | 86K words |
| 2024-05-08 | 2024-03-31 | 0000950170-24-055727 | EDGAR | 83K words |
| 2023-11-08 | 2023-09-30 | 0000950170-23-061171 | EDGAR | 86K words |
| 2023-08-03 | 2023-06-30 | 0000950170-23-038050 | EDGAR | 83K words |
| 2023-05-08 | 2023-03-31 | 0001564590-23-007074 | EDGAR | 81K words |
| 2022-11-02 | 2022-09-30 | 0001564590-22-036375 | EDGAR | 81K words |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-11-05 | 0001193125-26-449791 | EDGAR | 5K words |
| 2026-09-08 | 0001193125-26-384405 | EDGAR | 2K words |
| 2026-08-10 | 0001193125-26-342371 | EDGAR | 5K words |
| 2026-03-03 | 0001193125-26-088203 | EDGAR | 5K words |
| 2026-02-17 | 0001193125-26-053294 | EDGAR | 1K words |
| 2026-01-14 | 0001193125-26-012664 | EDGAR | 2K words |
| 2025-11-06 | 0001193125-25-269522 | EDGAR | 5K words |
| 2025-09-05 | 0001193125-25-196414 | EDGAR | 1K words |
| 2025-08-29 | 0001193125-25-192766 | EDGAR | 1K words |
| 2025-08-11 | 0001770121-25-000009 | EDGAR | 5K words |
99 total filings indexed. 71 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001770121 |
| Ticker | SANA |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.sana.com |
| Listed | 2021-02-04 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/SANA (~200 tokens, structured JSON with cryptographic provenance)